PUBLISHER: TechNavio | PRODUCT CODE: 2109480
PUBLISHER: TechNavio | PRODUCT CODE: 2109480
Global Amyotrophic Lateral Sclerosis Treatment Market 2026-2030
The global amyotrophic lateral sclerosis treatment market is forecasted to grow by USD 200.4 mn during 2025-2030, accelerating at a CAGR of 4.5% during the forecast period. The report on the global amyotrophic lateral sclerosis treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in precision medicine and genetically targeted therapies, favorable regulatory frameworks and accelerated clinical development pathways, expansion of specialized healthcare infrastructure and diagnostic capabilities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 4.4% |
| CAGR | 4.5% |
| Incremental Value | $200.4 mn |
Technavio's global amyotrophic lateral sclerosis treatment market is segmented as below:
By Route Of Administration
- Intravenous
- Oral
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Drug Class
- Riluzole
- Symptomatic treatments
- Edaravone
- Muscle relaxants
- Antisense oligonucleotides
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the integration of ai and digital biomarkers in clinical research as one of the prime reasons driving the global amyotrophic lateral sclerosis treatment market growth during the next few years. Also, shift toward combination therapies and multi-targeted mechanistic approaches and decentralized clinical trials and enhanced patient-centric frameworks will lead to sizable demand in the market.
The report on the global amyotrophic lateral sclerosis treatment market covers the following areas:
- Global amyotrophic lateral sclerosis treatment market sizing
- Global amyotrophic lateral sclerosis treatment market forecast
- Global amyotrophic lateral sclerosis treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global amyotrophic lateral sclerosis treatment market vendors that include AB Science SA, Alkem Laboratories Ltd., Apotex Inc., Aquestive Therapeutics Inc, Biogen Inc., CorestemChemon Inc., Cytokinetics Inc., Dr. Reddys Laboratories Ltd., Ionis Pharmaceuticals Inc., Italfarmaco Holding SPA, Otsuka Holdings Co. Ltd., Revalesio Corp., Sanofi SA, Sun Pharmaceutical Industries, The Mitsubishi Chemical Group, Treeway BV. Also, the global amyotrophic lateral sclerosis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Amyotrophic Lateral Sclerosis Treatment Market 2020 - 2024
- Historic Market Size - Data Table on Global Amyotrophic Lateral Sclerosis Treatment Market 2020 - 2024 ($ million)
- 5.2 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.3 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
- 5.4 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Amyotrophic Lateral Sclerosis Treatment Market
- 6.2 Impact of geopolitical conflicts on Global Amyotrophic Lateral Sclerosis Treatment Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Route of Administration
- 8.1 Market segments
- 8.2 Comparison by Route of Administration
- 8.3 Intravenous - Market size and forecast 2025-2030
- 8.4 Oral - Market size and forecast 2025-2030
- 8.5 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
9 Market Segmentation by Distribution Channel
- 9.1 Market segments
- 9.2 Comparison by Distribution Channel
- 9.3 Hospital pharmacies - Market size and forecast 2025-2030
- 9.4 Retail pharmacies - Market size and forecast 2025-2030
- 9.5 Online pharmacies - Market size and forecast 2025-2030
- 9.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
10 Market Segmentation by Drug Class
- 10.1 Market segments
- 10.2 Comparison by Drug Class
- 10.3 Riluzole - Market size and forecast 2025-2030
- 10.4 Symptomatic treatments - Market size and forecast 2025-2030
- 10.5 Edaravone - Market size and forecast 2025-2030
- 10.6 Muscle relaxants - Market size and forecast 2025-2030
- 10.7 Antisense oligonucleotides - Market size and forecast 2025-2030
- 10.8 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 Japan - Market size and forecast 2025-2030
- 12.5.2 China - Market size and forecast 2025-2030
- 12.5.3 India - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Singapore - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Australia - Market size and forecast 2025-2030
- 12.6.2 Brazil - Market size and forecast 2025-2030
- 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.4 Argentina - Market size and forecast 2025-2030
- 12.6.5 South Africa - Market size and forecast 2025-2030
- 12.6.6 UAE - Market size and forecast 2025-2030
- 12.6.7 Chile - Market size and forecast 2025-2030
- 12.6.8 New Zealand - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rise in precision medicine and genetically targeted therapies
- Favorable regulatory frameworks and accelerated clinical development pathways
- Expansion of specialized healthcare infrastructure and diagnostic capabilities
- 13.2 Market challenges
- High attrition rates and late-stage clinical trial failures
- Prohibitive treatment costs and complex reimbursement obstacles
- Specialized manufacturing and supply chain complexities
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Integration of AI and digital biomarkers in clinical research
- Shift toward combination therapies and multi-targeted mechanistic approaches
- Decentralized clinical trials and enhanced patient-centric frameworks
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AB Science SA
- AB Science SA - Overview
- AB Science SA - Product / Service
- AB Science SA - Key offerings
- SWOT
- 15.5 Alkem Laboratories Ltd.
- Alkem Laboratories Ltd. - Overview
- Alkem Laboratories Ltd. - Business segments
- Alkem Laboratories Ltd. - Key offerings
- Alkem Laboratories Ltd. - Segment focus
- SWOT
- 15.6 Apotex Inc.
- Apotex Inc. - Overview
- Apotex Inc. - Product / Service
- Apotex Inc. - Key offerings
- SWOT
- 15.7 Aquestive Therapeutics Inc
- Aquestive Therapeutics Inc - Overview
- Aquestive Therapeutics Inc - Product / Service
- Aquestive Therapeutics Inc - Key offerings
- SWOT
- 15.8 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key news
- Biogen Inc. - Key offerings
- SWOT
- 15.9 CorestemChemon Inc.
- CorestemChemon Inc. - Overview
- CorestemChemon Inc. - Product / Service
- CorestemChemon Inc. - Key offerings
- SWOT
- 15.10 Cytokinetics Inc.
- Cytokinetics Inc. - Overview
- Cytokinetics Inc. - Product / Service
- Cytokinetics Inc. - Key offerings
- SWOT
- 15.11 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
- 15.12 Ionis Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc. - Overview
- Ionis Pharmaceuticals Inc. - Product / Service
- Ionis Pharmaceuticals Inc. - Key news
- Ionis Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.13 Italfarmaco Holding SPA
- Italfarmaco Holding SPA - Overview
- Italfarmaco Holding SPA - Product / Service
- Italfarmaco Holding SPA - Key offerings
- SWOT
- 15.14 Otsuka Holdings Co. Ltd.
- Otsuka Holdings Co. Ltd. - Overview
- Otsuka Holdings Co. Ltd. - Business segments
- Otsuka Holdings Co. Ltd. - Key offerings
- Otsuka Holdings Co. Ltd. - Segment focus
- SWOT
- 15.15 Revalesio Corp.
- Revalesio Corp. - Overview
- Revalesio Corp. - Product / Service
- Revalesio Corp. - Key offerings
- SWOT
- 15.16 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.17 Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries - Overview
- Sun Pharmaceutical Industries - Business segments
- Sun Pharmaceutical Industries - Key news
- Sun Pharmaceutical Industries - Key offerings
- Sun Pharmaceutical Industries - Segment focus
- SWOT
- 15.18 The Mitsubishi Chemical Group
- The Mitsubishi Chemical Group - Overview
- The Mitsubishi Chemical Group - Business segments
- The Mitsubishi Chemical Group - Key news
- The Mitsubishi Chemical Group - Key offerings
- The Mitsubishi Chemical Group - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
